An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.
Fiche publication
Date publication
juin 2016
Journal
BMJ open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent, Dr DABAKUYO-YONLI Sandrine, Pr HILLON Patrick, Dr JOUVE Jean-Louis, Dr MINELLO Anne
Tous les auteurs :
Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B, Bonnetain F
Lien Pubmed
Résumé
The objective of this study was to explore the association between health-related quality of life (HRQoL) and the recommended phase 2 dose in a phase I clinical trial according to the Time to HRQoL deterioration approach (TTD).
Mots clés
Health-related Quality of Life, longitudinal analysis, oncology clinical trial, phase I, time to deterioration
Référence
BMJ Open. 2016 Jun;6(6):e010696